Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination.
Animals
Antineoplastic Agents, Alkylating
/ pharmacology
Apoptosis
Biomarkers, Tumor
Brain Neoplasms
/ drug therapy
Cell Nucleus
/ genetics
Cell Proliferation
Cellular Senescence
DNA Damage
DNA Repair
Drug Resistance, Neoplasm
Female
Gene Expression Regulation, Neoplastic
Glioblastoma
/ drug therapy
Homologous Recombination
Humans
Mice
Mice, Nude
Survivin
/ genetics
Temozolomide
/ pharmacology
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Alkylation damage
BIRC5
Clastogenic effects
Inhibitor of apoptosis (IAP)
Nuclear export signal
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
25
01
2021
accepted:
22
05
2021
revised:
20
05
2021
pubmed:
9
6
2021
medline:
10
7
2021
entrez:
8
6
2021
Statut:
ppublish
Résumé
To clarify whether differential compartmentalization of Survivin impacts temozolomide (TMZ)-triggered end points, we established a well-defined glioblastoma cell model in vitro (LN229 and A172) and in vivo, distinguishing between its nuclear and cytoplasmic localization. Expression of nuclear export sequence (NES)-mutated Survivin (SurvNESmut-GFP) led to impaired colony formation upon TMZ. This was not due to enhanced cell death but rather due to increased senescence. Nuclear-trapped Survivin reduced homologous recombination (HR)-mediated double-strand break (DSB) repair, as evaluated by γH2AX foci formation and qPCR-based HR assay leading to pronounced induction of chromosome aberrations. Opposite, clones, expressing free-shuttling cytoplasmic but not nuclear-trapped Survivin, could repair TMZ-induced DSBs and evaded senescence. Mass spectrometry-based interactomics revealed, however, no direct interaction of Survivin with any of the repair factors. The improved TMZ-triggered HR activity in Surv-GFP was associated with enhanced mRNA and stabilized RAD51 protein expression, opposite to diminished RAD51 expression in SurvNESmut cells. Notably, cytoplasmic Survivin could significantly compensate for the viability under RAD51 knockdown. Differential Survivin localization also resulted in distinctive TMZ-triggered transcriptional pathways, associated with senescence and chromosome instability as shown by global transcriptome analysis. Orthotopic LN229 xenografts, expressing SurvNESmut exhibited diminished growth and increased DNA damage upon TMZ, as manifested by PCNA and γH2AX foci expression, respectively, in brain tissue sections. Consequently, those mice lived longer. Although tumors of high-grade glioma patients expressed majorly nuclear Survivin, they exhibited rarely NES mutations which did not correlate with survival. Based on our in vitro and xenograft data, Survivin nuclear trapping would facilitate glioma response to TMZ.
Identifiants
pubmed: 34100981
doi: 10.1007/s00018-021-03864-0
pii: 10.1007/s00018-021-03864-0
pmc: PMC8257519
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
BIRC5 protein, human
0
Biomarkers, Tumor
0
Survivin
0
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5587-5604Subventions
Organisme : Deutsche Krebshilfe
ID : 70111404
Organisme : Deutsche Forschungsgemeinschaft
ID : DFG-CH 665/6-1
Organisme : Wilhelm Sander-Stiftung
ID : 2019.154.1
Références
J Neurooncol. 2009 Feb;91(3):353-8
pubmed: 18953492
In Vitro Cell Dev Biol Anim. 2017 Mar;53(3):258-264
pubmed: 27826797
Arch Toxicol. 2019 Aug;93(8):2265-2277
pubmed: 31289894
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
J Transl Med. 2018 Mar 23;16(1):79
pubmed: 29571296
Oncotarget. 2017 Feb 28;8(9):15071-15084
pubmed: 28122345
J Neurosurg. 2018 Mar;128(3):679-684
pubmed: 28430038
Int J Clin Pharmacol Ther. 2002 Aug;40(8):354-67
pubmed: 12467304
FASEB J. 2007 Jan;21(1):207-16
pubmed: 17099069
Int J Cancer. 2005 Apr 20;114(4):509-12
pubmed: 15578717
Radiother Oncol. 2011 Oct;101(1):51-8
pubmed: 21852011
Genes (Basel). 2019 Jan 09;10(1):
pubmed: 30634491
Gerontology. 2016;62(2):173-81
pubmed: 26159786
Cell Death Dis. 2017 Jan 5;8(1):e2533
pubmed: 28055005
Cell Rep. 2019 Apr 23;27(4):997-1007.e5
pubmed: 31018144
EMBO Rep. 2006 Dec;7(12):1259-65
pubmed: 17099693
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
Nature. 2011 Nov 09;479(7374):547-51
pubmed: 22080947
Hum Mutat. 2013 Feb;34(2):395-404
pubmed: 23161837
Ann Neurol. 2011 Jul;70(1):9-21
pubmed: 21786296
Cancer Res. 2019 Jan 1;79(1):99-113
pubmed: 30361254
J Cell Biol. 2008 Oct 20;183(2):279-96
pubmed: 18936249
DNA Repair (Amst). 2009 Jan 1;8(1):72-86
pubmed: 18840549
Cell Death Dis. 2010 Jul 22;1:e57
pubmed: 21364662
Int J Mol Sci. 2020 Jan 30;21(3):
pubmed: 32019108
Cancer Res. 2007 Jul 1;67(13):5999-6002
pubmed: 17616652
Cell Cycle. 2015;14(3):297-304
pubmed: 25564883
Oncotarget. 2017 Apr 25;8(17):27754-27771
pubmed: 27487141
Cell Signal. 2014 Dec;26(12):2773-81
pubmed: 25192910
Oncotarget. 2015 Dec 8;6(39):41402-17
pubmed: 26595675
Aging Cell. 2015 Aug;14(4):644-58
pubmed: 25754370
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Prog Cell Cycle Res. 2003;5:447-52
pubmed: 14593739
Cell. 2008 Jun 13;133(6):1006-18
pubmed: 18555777
Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):8971-6
pubmed: 22615382
Oncogene. 2018 Jan 25;37(4):534-543
pubmed: 28991226
Nat Commun. 2019 Jun 28;10(1):2854
pubmed: 31253781
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Breast Cancer Res Treat. 2016 Jan;155(1):53-63
pubmed: 26679694
N Engl J Med. 2008 Jul 31;359(5):492-507
pubmed: 18669428
Mol Cancer Ther. 2016 Nov;15(11):2665-2678
pubmed: 27474153
FEBS J. 2012 Aug;279(15):2610-23
pubmed: 22621751
Am J Transl Res. 2017 May 15;9(5):2163-2180
pubmed: 28559969
EMBO Rep. 2006 Jan;7(1):85-92
pubmed: 16239925
Cancers (Basel). 2020 Mar 01;12(3):
pubmed: 32121554
Nature. 2007 Feb 8;445(7128):656-60
pubmed: 17251933
Mol Cancer Ther. 2017 Jan;16(1):156-168
pubmed: 27777286
Cancer Res. 2021 May 1;81(9):2304-2317
pubmed: 33408118
Cancer Res. 2019 Oct 1;79(19):4937-4950
pubmed: 31416840
PLoS One. 2011;6(11):e27183
pubmed: 22073281
Oncotarget. 2015 Oct 20;6(32):33755-68
pubmed: 26418950